APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccine for Chickenpox

Compare research editions
View pricing & licenses

Selected research

Industry Research

Live Attenuated Vaccine for Chickenpox Industry Research Report 2026

29 December 2025124 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccine for Chickenpox Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccine for Chickenpox Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccine for Chickenpox Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccine for Chickenpox Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccine for Chickenpox market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Live Attenuated Vaccine for Chickenpox is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccine for Chickenpox is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Live Attenuated Vaccine for Chickenpox include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Live Attenuated Vaccine for Chickenpox market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Live Attenuated Vaccine for Chickenpox Market by Company

GSK

BCHT

Biken

Green Cross

Keygen

Merck & Co lnc

Sanofi Pasteur

Beijing Institute of Biological Products Co., Ltd

Chengdu Institute of Biological Products Co., Ltd

Kexing (Dalian) Vaccine Technology Co., Ltd

Shanghai Rongsheng Biopharmaceutical Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Changchun Baike Biotechnology Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Vaccine for Chickenpox Segment by Type

Child

Adult

Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital

Clinic

Live Attenuated Vaccine for Chickenpox Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Live Attenuated Vaccine for Chickenpox by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Live Attenuated Vaccine for Chickenpox in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Live Attenuated Vaccine for Chickenpox Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Live Attenuated Vaccine for Chickenpox Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Manufacturers (2021-2026) Table 8. Global Live Attenuated Vaccine for Chickenpox Revenue of Manufacturers (2021-2026) Table 9. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Live Attenuated Vaccine for Chickenpox Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Live Attenuated Vaccine for Chickenpox Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Product Type & Application Table 14. Global Live Attenuated Vaccine for Chickenpox Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Live Attenuated Vaccine for Chickenpox by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. GSK Live Attenuated Vaccine for Chickenpox Product Portfolio Table 22. GSK Recent Developments Table 23. BCHT Company Information Table 24. BCHT Business Overview Table 25. BCHT Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio Table 27. BCHT Recent Developments Table 28. Biken Company Information Table 29. Biken Business Overview Table 30. Biken Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Biken Live Attenuated Vaccine for Chickenpox Product Portfolio Table 32. Biken Recent Developments Table 33. Green Cross Company Information Table 34. Green Cross Business Overview Table 35. Green Cross Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio Table 37. Green Cross Recent Developments Table 38. Keygen Company Information Table 39. Keygen Business Overview Table 40. Keygen Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio Table 42. Keygen Recent Developments Table 43. Merck & Co lnc Company Information Table 44. Merck & Co lnc Business Overview Table 45. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio Table 47. Merck & Co lnc Recent Developments Table 48. Sanofi Pasteur Company Information Table 49. Sanofi Pasteur Business Overview Table 50. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio Table 52. Sanofi Pasteur Recent Developments Table 53. Beijing Institute of Biological Products Co., Ltd Company Information Table 54. Beijing Institute of Biological Products Co., Ltd Business Overview Table 55. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 57. Beijing Institute of Biological Products Co., Ltd Recent Developments Table 58. Chengdu Institute of Biological Products Co., Ltd Company Information Table 59. Chengdu Institute of Biological Products Co., Ltd Business Overview Table 60. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 62. Chengdu Institute of Biological Products Co., Ltd Recent Developments Table 63. Kexing (Dalian) Vaccine Technology Co., Ltd Company Information Table 64. Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview Table 65. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 67. Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments Table 68. Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information Table 69. Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview Table 70. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 72. Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments Table 73. Shanghai Institute of Biological Products Co., Ltd Company Information Table 74. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 75. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 77. Shanghai Institute of Biological Products Co., Ltd Recent Developments Table 78. Changchun Baike Biotechnology Co., Ltd Company Information Table 79. Changchun Baike Biotechnology Co., Ltd Business Overview Table 80. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 82. Changchun Baike Biotechnology Co., Ltd Recent Developments Table 83. Changchun Qijian Biological Products Co., Ltd Company Information Table 84. Changchun Qijian Biological Products Co., Ltd Business Overview Table 85. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 87. Changchun Qijian Biological Products Co., Ltd Recent Developments Table 88. Global Live Attenuated Vaccine for Chickenpox Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026) & (K Units) Table 90. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2026) Table 91. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2027-2032) & (K Units) Table 92. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2027-2032) Table 93. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2021-2026) Table 95. Global Live Attenuated Vaccine for Chickenpox Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Region (2027-2032) Table 97. North America Live Attenuated Vaccine for Chickenpox Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 99. North America Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 100. North America Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Live Attenuated Vaccine for Chickenpox Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Live Attenuated Vaccine for Chickenpox Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 104. Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 105. Europe Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Live Attenuated Vaccine for Chickenpox Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Live Attenuated Vaccine for Chickenpox Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 114. South America Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 115. South America Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Live Attenuated Vaccine for Chickenpox Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2026) & (K Units) Table 123. Global Live Attenuated Vaccine for Chickenpox Sales by Type (2027-2032) & (K Units) Table 124. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2026) Table 125. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2027-2032) Table 126. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2026) Table 129. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2027-2032) Table 130. Global Live Attenuated Vaccine for Chickenpox Price by Type (2021-2026) & (US$/Unit) Table 131. Global Live Attenuated Vaccine for Chickenpox Price by Type (2027-2032) & (US$/Unit) Table 132. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2026) & (K Units) Table 133. Global Live Attenuated Vaccine for Chickenpox Sales by Application (2027-2032) & (K Units) Table 134. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2026) Table 135. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2027-2032) Table 136. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2026) Table 139. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2027-2032) Table 140. Global Live Attenuated Vaccine for Chickenpox Price by Application (2021-2026) & (US$/Unit) Table 141. Global Live Attenuated Vaccine for Chickenpox Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Live Attenuated Vaccine for Chickenpox Distributors List Table 145. Live Attenuated Vaccine for Chickenpox Customers List Table 146. Live Attenuated Vaccine for Chickenpox Industry Trends Table 147. Live Attenuated Vaccine for Chickenpox Industry Drivers Table 148. Live Attenuated Vaccine for Chickenpox Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Live Attenuated Vaccine for Chickenpox Product Image Figure 5. Global Live Attenuated Vaccine for Chickenpox Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Live Attenuated Vaccine for Chickenpox Market Size (2021-2032) & (US$ Million) Figure 7. Global Live Attenuated Vaccine for Chickenpox Sales (2021-2032) & (K Units) Figure 8. Global Live Attenuated Vaccine for Chickenpox Average Price (US$/Unit) & (2021-2032) Figure 9. Child Product Image Figure 10. Adult Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Live Attenuated Vaccine for Chickenpox Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Live Attenuated Vaccine for Chickenpox Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Live Attenuated Vaccine for Chickenpox Sales by Region in 2025 Figure 19. Global Live Attenuated Vaccine for Chickenpox Revenue by Region in 2025 Figure 20. North America Live Attenuated Vaccine for Chickenpox Market Size by Country in 2025 Figure 21. North America Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 22. North America Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2021-2032) Figure 23. United States Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Live Attenuated Vaccine for Chickenpox Market Size by Country in 2025 Figure 26. Europe Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 27. Europe Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2021-2032) Figure 28. Germany Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Live Attenuated Vaccine for Chickenpox Market Size by Country in 2025 Figure 34. Asia Pacific Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2021-2032) Figure 36. China Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Live Attenuated Vaccine for Chickenpox Market Size by Country in 2025 Figure 45. South America Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 46. South America Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2021-2032) Figure 47. Mexico Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Size by Country in 2025 Figure 51. Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue Market Share by Country (2021-2032) Figure 53. Turkey Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Live Attenuated Vaccine for Chickenpox Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032) Figure 57. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032) Figure 58. Global Live Attenuated Vaccine for Chickenpox Price (US$/Unit) by Type (2021-2032) Figure 59. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032) Figure 60. Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032) Figure 61. Global Live Attenuated Vaccine for Chickenpox Price (US$/Unit) by Application (2021-2032) Figure 62. Live Attenuated Vaccine for Chickenpox Value Chain Figure 63. Live Attenuated Vaccine for Chickenpox Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • BCHT
  • Biken
  • Green Cross
  • Keygen
  • Merck & Co lnc
  • Sanofi Pasteur
  • Beijing Institute of Biological Products Co., Ltd
  • Chengdu Institute of Biological Products Co., Ltd
  • Kexing (Dalian) Vaccine Technology Co., Ltd
  • Shanghai Rongsheng Biopharmaceutical Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Changchun Baike Biotechnology Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Live Attenuated Vaccine for Chickenpox Market Size (2021-2032)
  4. 2.2.2 Global Live Attenuated Vaccine for Chickenpox Sales (2021-2032)
  5. 2.2.3 Global Live Attenuated Vaccine for Chickenpox Market Average Price (2021-2032)
  6. 2.3 Live Attenuated Vaccine for Chickenpox by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Child
  9. 2.3.3 Adult
  10. 2.4 Live Attenuated Vaccine for Chickenpox by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Live Attenuated Vaccine for Chickenpox Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Live Attenuated Vaccine for Chickenpox Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Vaccine for Chickenpox Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Vaccine for Chickenpox Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Live Attenuated Vaccine for Chickenpox Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Product Type & Application
  8. 3.8 Global Manufacturers of Live Attenuated Vaccine for Chickenpox, Established Date
  9. 3.9 Global Live Attenuated Vaccine for Chickenpox Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 BCHT
  8. 4.2.1 BCHT Company Information
  9. 4.2.2 BCHT Business Overview
  10. 4.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
  12. 4.2.5 BCHT Recent Developments
  13. 4.3 Biken
  14. 4.3.1 Biken Company Information
  15. 4.3.2 Biken Business Overview
  16. 4.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
  18. 4.3.5 Biken Recent Developments
  19. 4.4 Green Cross
  20. 4.4.1 Green Cross Company Information
  21. 4.4.2 Green Cross Business Overview
  22. 4.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
  24. 4.4.5 Green Cross Recent Developments
  25. 4.5 Keygen
  26. 4.5.1 Keygen Company Information
  27. 4.5.2 Keygen Business Overview
  28. 4.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
  30. 4.5.5 Keygen Recent Developments
  31. 4.6 Merck & Co lnc
  32. 4.6.1 Merck & Co lnc Company Information
  33. 4.6.2 Merck & Co lnc Business Overview
  34. 4.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
  36. 4.6.5 Merck & Co lnc Recent Developments
  37. 4.7 Sanofi Pasteur
  38. 4.7.1 Sanofi Pasteur Company Information
  39. 4.7.2 Sanofi Pasteur Business Overview
  40. 4.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
  42. 4.7.5 Sanofi Pasteur Recent Developments
  43. 4.8 Beijing Institute of Biological Products Co., Ltd
  44. 4.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 4.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 4.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  48. 4.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 4.9 Chengdu Institute of Biological Products Co., Ltd
  50. 4.9.1 Chengdu Institute of Biological Products Co., Ltd Company Information
  51. 4.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
  52. 4.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  54. 4.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
  55. 4.10 Kexing (Dalian) Vaccine Technology Co., Ltd
  56. 4.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Company Information
  57. 4.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
  58. 4.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  60. 4.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
  61. 4.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
  62. 4.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information
  63. 4.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
  64. 4.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  66. 4.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
  67. 4.12 Shanghai Institute of Biological Products Co., Ltd
  68. 4.12.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  69. 4.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  70. 4.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  72. 4.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  73. 4.13 Changchun Baike Biotechnology Co., Ltd
  74. 4.13.1 Changchun Baike Biotechnology Co., Ltd Company Information
  75. 4.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
  76. 4.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  78. 4.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
  79. 4.14 Changchun Qijian Biological Products Co., Ltd
  80. 4.14.1 Changchun Qijian Biological Products Co., Ltd Company Information
  81. 4.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  82. 4.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  84. 4.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
5 Global Live Attenuated Vaccine for Chickenpox Market Scenario by Region
  1. 5.1 Global Live Attenuated Vaccine for Chickenpox Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021-2032
  3. 5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021-2026
  4. 5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2027-2032
  5. 5.3 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2021-2032
  6. 5.3.1 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2021-2026
  7. 5.3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Region: 2027-2032
  8. 5.4 North America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
  9. 5.4.1 North America Live Attenuated Vaccine for Chickenpox Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  11. 5.4.3 North America Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
  15. 5.5.1 Europe Live Attenuated Vaccine for Chickenpox Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  17. 5.5.3 Europe Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Live Attenuated Vaccine for Chickenpox Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
  35. 5.7.1 South America Live Attenuated Vaccine for Chickenpox Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  37. 5.7.3 South America Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Live Attenuated Vaccine for Chickenpox Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Live Attenuated Vaccine for Chickenpox Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032)
  2. 6.1.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Type (2021-2032)
  4. 6.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Type (2021-2032)
  5. 6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Live Attenuated Vaccine for Chickenpox Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032)
  2. 7.1.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Application (2021-2032)
  4. 7.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Application (2021-2032)
  5. 7.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Live Attenuated Vaccine for Chickenpox Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Live Attenuated Vaccine for Chickenpox Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
  2. 8.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Live Attenuated Vaccine for Chickenpox Production Mode & Process
  5. 8.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Live Attenuated Vaccine for Chickenpox Distributors
  8. 8.2.3 Live Attenuated Vaccine for Chickenpox Customers
9 Global Live Attenuated Vaccine for Chickenpox Analyzing Market Dynamics
  1. 9.1 Live Attenuated Vaccine for Chickenpox Industry Trends
  2. 9.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
  3. 9.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
  4. 9.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst